HC Wainwright Reiterates Buy Rating for Fractyl Health (NASDAQ:GUTS)

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $8.00 target price on the stock.

Several other analysts also recently issued reports on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Stock Up 6.7%

GUTS stock opened at $0.62 on Friday. The company has a market cap of $98.36 million, a P/E ratio of -0.34 and a beta of 1.20. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03. The company’s 50-day moving average price is $0.48 and its 200 day moving average price is $1.18. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34. On average, research analysts expect that Fractyl Health will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in Fractyl Health during the second quarter worth approximately $31,000. FNY Investment Advisers LLC acquired a new position in Fractyl Health during the third quarter worth approximately $31,000. Jump Financial LLC acquired a new position in Fractyl Health during the fourth quarter worth approximately $57,000. Scientech Research LLC acquired a new position in Fractyl Health during the third quarter worth approximately $49,000. Finally, Prelude Capital Management LLC acquired a new position in Fractyl Health during the third quarter worth approximately $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.